Stanley Frankel - Concepedia

Author

Stanley Frankel

Memorial Sloan Kettering Cancer Center

Also Known As

S Frankel, S. Frankel, S. K. Frankel, Stanley Frankel

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Roswell Park Comprehensive Cancer Center University of Maryland, Baltimore Massachusetts General Hospital University of Iowa

About

Stanley Frankel is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, immunology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	369
2	Health Sciences	2	2	101
3	Engineering	1	1	142
4	Natural Sciences	1	1	142
5	Applied Physics	1	1	142

Stanley Frankel

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz, Journal of Clinical Oncology	2005	402
Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study Howard S. Höchster, Edie Weller, Randy D. Gascoyne, Journal of Clinical Oncology	2009	277
Calculations in the Liquid-Drop Model of Fission Stanley Frankel, N. Metropolis Physical Review EngineeringPolar RepresentationPhysicsNuclear FissionNatural Sciences	1947	142
High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507) Yixuan Gong, Evelyn Yao, Ronglai Shen, PLoS ONE	2009	128
Hydroxychloroquine for the treatment of chronic graft-versus-host disease Andrew L. Gilman, Ka-Wah Chan, Mark Mogul, Biology of Blood and Marrow Transplantation	2000	109
Rituximab as Successful Adjunct Treatment in a Patient With Disseminated Nontuberculous Mycobacterial Infection Due to Acquired Anti-Interferon- Autoantibody Christopher A. Czaja, Patricia Merkel, Edward D. Chan, Clinical Infectious Diseases ImmunodeficienciesHumoral ResponseImmunologyDrug ResistanceMedical Microbiology	2013	87
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195 Eric J. Feldman, M Kalaycio, George J. Weiner, Leukemia Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaImmunologyHematology	2003	85
The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R Wyndham H. Wilson, Martin Gutierrez, Paula G. O’Connor, Seminars in Oncology Hematological MalignancyLymphoid NeoplasiaAggressive B-cell LymphomaMedicinePreliminary Report	2002	82
Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients Stefania D’Atri, Daniela Piccioni, Aurora Castellano, Annals of Oncology Hematological MalignancyO6-alkylguanine-dna Alkyltransferase LevelsMixed-phenotype Acute LeukemiaMalignant Blood DisorderMolecular Biology	1995	53
The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide Owen A. O’Connor, Emily A. Smith, Lorraine E. Toner, Clinical Cancer Research	2006	46

Page 1